- Home
- WHG vs CRDF Comparison
WHG vs CRDF Comparison
Compare WHG & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WHG
- CRDF
- Stock Information
- Founded
- WHG 1983
- CRDF 1999
- Country
- WHG United States
- CRDF United States
- Employees
- WHG N/A
- CRDF N/A
- Industry
- WHG Investment Managers
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WHG Finance
- CRDF Health Care
- Exchange
- WHG Nasdaq
- CRDF Nasdaq
- Market Cap
- WHG 146.3M
- CRDF 169.6M
- IPO Year
- WHG 2002
- CRDF N/A
- Fundamental
- Price
- WHG $14.56
- CRDF $3.35
- Analyst Decision
- WHG
- CRDF Strong Buy
- Analyst Count
- WHG 0
- CRDF 4
- Target Price
- WHG N/A
- CRDF $12.25
- AVG Volume (30 Days)
- WHG 16.5K
- CRDF 874.0K
- Earning Date
- WHG 04-30-2025
- CRDF 05-08-2025
- Dividend Yield
- WHG 4.06%
- CRDF N/A
- EPS Growth
- WHG N/A
- CRDF N/A
- EPS
- WHG 0.04
- CRDF N/A
- Revenue
- WHG $95,241,000.00
- CRDF $587,000.00
- Revenue This Year
- WHG N/A
- CRDF N/A
- Revenue Next Year
- WHG N/A
- CRDF N/A
- P/E Ratio
- WHG $309.53
- CRDF N/A
- Revenue Growth
- WHG 6.08
- CRDF N/A
- 52 Week Low
- WHG $11.11
- CRDF $2.01
- 52 Week High
- WHG $18.03
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- WHG 38.75
- CRDF 63.95
- Support Level
- WHG $14.78
- CRDF $2.81
- Resistance Level
- WHG $15.46
- CRDF $3.08
- Average True Range (ATR)
- WHG 0.43
- CRDF 0.20
- MACD
- WHG -0.02
- CRDF 0.08
- Stochastic Oscillator
- WHG 4.72
- CRDF 76.53
About WHG Westwood Holdings Group Inc
Westwood Holdings Group Inc manages investment assets and provides services for clients through subsidiaries. It operates its business through the Advisory and Trust segments. Its advisory segment provides investment advisory services to corporate retirement plans, public retirement plans, endowments, foundations, individuals and the Westwood Funds, as well as investment sub-advisory services to mutual funds and its trust segment. The Trust segment offers trust and custodial services to its clients and its advisory segment sponsors common trust funds to institutions and high net-worth individuals. It generates maximum revenue from the Advisory segment. Geographically, it derives a majority of its revenue from the United States.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.